Table 1.
Vaccines containing S. aureus antigens that have been evaluated in human clinical trials as reported on clinicaltrials.gov.
| Sponsor | Vaccine | Antigens | Clinicaltrials.gov identifier | Clinical Study Phase |
|---|---|---|---|---|
| Nabi | StaphVAXa | CP8 conjugate, CP5 conjugate | NCT00071214 | 3 |
| NCT00130260 | 3 | |||
| NCT00211900 | 3 | |||
| NCT00211913 | 3 | |||
| NCT00211926 | 3 | |||
| NCT00211965 | 3 | |||
| NCT00211991 | 3 | |||
| GSK | GSK2392 | 4-component | NCT01160172 | 1 |
| Pfizer | SA3Ag | CP8 conjugate, CP5 conjugate, clumping factor A | NCT01018641 | 1 |
| SA4Ag | Same as SA3Ag plus manganese transporter C | NCT01364571 | 1 | |
| SA4Ag and SA3Ag | NCT01643941 | 1, 2 | ||
| Merck | V710a | Iron surface determinant B | NCT00303069 | 1 |
| NCT01324440 | 1 | |||
| NCT00735839 | 1 | |||
| NCT00822757 | 1 | |||
| NCT00572910 | 2 | |||
| NCT00518687 | 2, 3 | |||
| NIAID | STEBvax | Enterotoxin B | NCT00974935 | 1 |
| Uniformed services | Monovalents | Alpha toxin | NCT01011335 | 1, 2 |
| University of the Health Sciences | Panton–Valentine leukocidin toxoid | |||
| Bivalent | Alpha toxin, Panton–Valentine leukocidin toxoid |
aDevelopment terminated.
CP, capsular polysaccharide.